FDA Approves First Blood Test for Early Alzheimer's Diagnosis

The FDA's approval of Lumipulse, a new blood test for Alzheimer's, marks a significant advancement in early diagnosis. This less invasive test, developed by Fujirebio Diagnostics, detects amyloid plaques in adults over 55 exhibiting symptoms. "The new test offers an option less invasive than traditional methods," states the FDA. The agency emphasizes that the results should be interpreted alongside other clinical data. This breakthrough allows for earlier intervention, potentially improving outcomes for Alzheimer's patients. The test's accessibility and less invasive nature are expected to increase early diagnosis rates.